GT-103
- Generic Name
- GT-103
Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
Phase 2
Active, not recruiting
- Conditions
- Recurrent Non Small Cell Lung CancerNon Small Cell Lung CancerMetastatic NSCLC
- Interventions
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Jeffrey Clarke
- Target Recruit Count
- 21
- Registration Number
- NCT05617313
- Locations
- 🇺🇸
University of Virginia Health System, Charlottesville, Virginia, United States
🇺🇸University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Edward Patz
- Target Recruit Count
- 31
- Registration Number
- NCT04314089
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Advent Health, Celebration, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath